|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2003
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD
1 University of Milan, San Paolo Hospital, Respiratory Unit, Milan, Italy. 2 Meakins-Cristie Laboratories, McGill University, Montreal, Quebec, Canada. 3 Institute of Respiratory Diseases, University of Milan IRCCS, Ospedale Maggiore, Milan, Italy. 4 Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A. Cardarelli Hospital, Naples, Italy
CORRESPONDENCE: S. Centanni, San Paolo Hospital, 20142, Milan, Italy. Fax: 39 0289123960. E-mail: stefano.centanni@unimi.it
Keywords: dynamic hyperinflation, expiratory flow limitation, formoterol, oxitropium, salbutamol, salmeterol
Received: March 12, 2002
Accepted August 22, 2002
It has been shown that patients with chronic obstructive pulmonary disease (COPD) develop dynamic hyperinflation (DH), which contributes to dyspnoea and exercise intolerance. Formoterol, salmeterol and oxitropium have been recommended for maintenance therapy in COPD patients, but their effect on DH has only been assessed for salmeterol.
The aim of the present study was to compare the acute effect of four inhaled bronchodilators (salbutamol, formoterol, salmeterol and oxitropium) and placebo on forced expiratory volume in one second, inspiratory capacity, forced vital capacity and dyspnoea in COPD patients. A cross-over, randomised, double-blind, placebo-controlled study was carried out on 20 COPD patients.
Patients underwent pulmonary function testing and dyspnoea evaluation, in basal condition and 5, 15, 30, 60 and 120 min after bronchodilator or placebo administration.
The results indicate that in chronic obstructive pulmonary disease patients with decreased baseline inspiratory capacity, there was a much greater increase of inspiratory capacity after bronchodilator administration, which correlated closely with the improvement of dyspnoea sensation at rest. For all bronchodilators used, inspiratory capacity reversibility should be tested at 30 min following the bronchodilator. On average, formoterol elicited the greatest increase in inspiratory capacity than the other bronchodilators used, though the difference was significant only with salmeterol and oxitropium. The potential advantage of formoterol needs to be tested in a larger patient population.
This article has been cited by other articles:
|
|
 |
|
  T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. Kessler Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 741 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Chen, S. G Bollmeier, and P. M Finnegan Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease Ann. Pharmacother., December 1, 2008; 42(12): 1832 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proceedings of the ATS, January 1, 2006; 3(2): 180 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, and on behalf of the TRISTAN study group Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease Thorax, April 1, 2005; 60(4): 301 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Casanova, C. Cote, J. P. de Torres, A. Aguirre-Jaime, J. M. Marin, V. Pinto-Plata, and B. R. Celli Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue Therapeutic Responses in Asthma and COPD: Bronchodilators Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Gosselink Breathing techniques in patients with chronic obstructive pulmonary disease (COPD) Chronic Respiratory Disease, July 1, 2004; 1(3): 163 - 172. [Abstract] [PDF]
|
|
|
|
|
|
N. Scichilone, R. Marchese, F. Catalano, A. M. Vignola, A. Togias, and V. Bellia Bronchodilatory Effect of Deep Inspiration Is Absent in Subjects With Mild COPD Chest, June 1, 2004; 125(6): 2029 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pecchiari, A. Pelucchi, E. D'Angelo, A. Foresi, J. Milic-Emili, and E. D'Angelo Effect of Heliox Breathing on Dynamic Hyperinflation in COPD Patients Chest, June 1, 2004; 125(6): 2075 - 2082. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |